search
Back to results

A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

Primary Purpose

Type 1 Diabetes, Type 2 Diabetes

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Harmony 1 Sensor
Sponsored by
Medtronic Diabetes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 1 Diabetes focused on measuring Type 1 Diabetes, Type 2 Diabetes, Harmony 1

Eligibility Criteria

2 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is 2-75 years of age at time of screening
  • A clinical diagnosis of type 1 or 2 diabetes for a minimum of 12 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  • Adequate venous access as assessed by investigator or appropriate staff
  • Subjects participating in the high and low glucose challenges must have an established insulin carbohydrate ratio(s) and insulin sensitivity ratio. (The term "established" refers to a ratio that has been previously defined and tested prior to screening visit). Subjects without established ratios may participate under observation only.

Exclusion Criteria:

  • Subject will not tolerate tape adhesive in the area of Harmony 1 Sensor placement as assessed by qualified individuals
  • Subject has any unresolved adverse skin condition in the area of Harmony 1 Sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)
  • Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks
  • Subject is female and has a positive pregnancy screening test
  • Females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator
  • Subject is female and plans to become pregnant during the course of the study
  • Subject has had a hypoglycemic seizure within the past 6 months
  • Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to screening visit
  • Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to screening visit.
  • Subject has a history of a seizure disorder
  • Subject has central nervous system or cardiac disorder resulting in syncope
  • Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  • Subject has a hematocrit (Hct) lower than the normal reference range
  • Subject has a history of adrenal insufficiency

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Group A

    Arm Description

    Subjects wearing Harmony 1 Sensor for up to 10 days.

    Outcomes

    Primary Outcome Measures

    Harmony 1 Sensor accuracy
    Sensor accuracy will be evaluated compared to YSI plasma glucose values during frequent sample testing. A within 30% mean agreement rate (±22.5 mg/dL when Reference BG ≤ 75 mg/dL) between sensor and YSI will be evaluated against the null Hypothesis for varying glucose ranges.

    Secondary Outcome Measures

    Full Information

    First Posted
    May 12, 2015
    Last Updated
    September 28, 2020
    Sponsor
    Medtronic Diabetes
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02456922
    Brief Title
    A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
    Official Title
    A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2020
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    For administraive reasons
    Study Start Date
    July 2018 (Anticipated)
    Primary Completion Date
    December 2018 (Anticipated)
    Study Completion Date
    December 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Medtronic Diabetes

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to demonstrate the performance of the Harmony 1 Sensor in subjects age 2 - 75 years
    Detailed Description
    This study is a multi-center, randomized, prospective single-sample correlational design without controls. A total of up to 310 previously-diagnosed type 1 or 2 diabetes subjects will be enrolled in order to have 160 subjects complete frequent sample testing at up to 17 centers. Subjects will wear Harmony 1 sensors used with the Guardian Mobile application.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 1 Diabetes, Type 2 Diabetes
    Keywords
    Type 1 Diabetes, Type 2 Diabetes, Harmony 1

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Group A
    Arm Type
    Other
    Arm Description
    Subjects wearing Harmony 1 Sensor for up to 10 days.
    Intervention Type
    Device
    Intervention Name(s)
    Harmony 1 Sensor
    Intervention Description
    Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
    Primary Outcome Measure Information:
    Title
    Harmony 1 Sensor accuracy
    Description
    Sensor accuracy will be evaluated compared to YSI plasma glucose values during frequent sample testing. A within 30% mean agreement rate (±22.5 mg/dL when Reference BG ≤ 75 mg/dL) between sensor and YSI will be evaluated against the null Hypothesis for varying glucose ranges.
    Time Frame
    10 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    2 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject is 2-75 years of age at time of screening A clinical diagnosis of type 1 or 2 diabetes for a minimum of 12 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis Adequate venous access as assessed by investigator or appropriate staff Subjects participating in the high and low glucose challenges must have an established insulin carbohydrate ratio(s) and insulin sensitivity ratio. (The term "established" refers to a ratio that has been previously defined and tested prior to screening visit). Subjects without established ratios may participate under observation only. Exclusion Criteria: Subject will not tolerate tape adhesive in the area of Harmony 1 Sensor placement as assessed by qualified individuals Subject has any unresolved adverse skin condition in the area of Harmony 1 Sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection) Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks Subject is female and has a positive pregnancy screening test Females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator Subject is female and plans to become pregnant during the course of the study Subject has had a hypoglycemic seizure within the past 6 months Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to screening visit Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to screening visit. Subject has a history of a seizure disorder Subject has central nervous system or cardiac disorder resulting in syncope Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease Subject has a hematocrit (Hct) lower than the normal reference range Subject has a history of adrenal insufficiency
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ronald Brazg, MD
    Organizational Affiliation
    Rainier Clinical Research Center
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Mark Christiansen, MD
    Organizational Affiliation
    Diablo Clinical Research
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Timothy Bailey, MD
    Organizational Affiliation
    AMCR Institute
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Satish Garg, MD
    Organizational Affiliation
    Barbara Davis Center
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Robert Slover, MD
    Organizational Affiliation
    Barbara Davis Center
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Kevin Kaiserman, MD
    Organizational Affiliation
    SoCal Diabetes
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Bruce Bode, MD
    Organizational Affiliation
    Atlanta Diabetes Associates
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Luis Casaubon, MD
    Organizational Affiliation
    Texas Diabetes & Endocrinology
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

    We'll reach out to this number within 24 hrs